Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06313593 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
A Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 186
- Enrollment target
- 20
- Study locations
NCT06313593: Recruiting Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.
NCT06313593 is a Phase 1 study of Myeloproliferative Neoplasms that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 186 participants, above the 128-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06313593, a Phase 1 study of Myeloproliferative Neoplasms, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 186 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
Primary Outcome
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.
Conditions Studied
Interventions
- DRUG Standard disease-directed therapy
- DRUG INCB160058
Study Locations (20)
New York
- Cornell Medical Center - New York
- Icahn School of Medicine At Mount Sinai - New York
- Sloan Kettering Institute For Cancer Research - New York
Other
- Hospital Saint Louis - Paris
- Institut Gustave Roussy - Villejuif
- University Medical Center Rwth Aachen - Aachen
Quebec
- Hopital Maisonneuve-Rosemont, Montreal, Qc - Montreal
- McGill University Jewish General Hospital - Montreal
Alabama
- The University of Alabama At Birmingham - Birmingham
California
- Stanford University - Palo Alto
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern University - Chicago
Kansas
- The University of Kansas Cancer Center Kucc University of Kansas Clinical Research Center - Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2028-10-09 |
| Phase | Phase 1 |
What NCT06313593 shows while recruiting
NCT06313593 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, above the 128-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Myeloproliferative Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Standard disease-directed therapy is the first listed.
NCT06313593 names 20 study sites across 15 states, led by New York, Other, Quebec.
Frequently Asked Questions
What is clinical trial NCT06313593 about?
NCT06313593 is a clinical study titled "A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms". This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
What is the current status of trial NCT06313593?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 186 participants. The study started on 2024-08-08. Estimated completion is 2028-10-09.
What conditions does trial NCT06313593 study?
This clinical trial studies the following conditions: Myeloproliferative Neoplasms.
What interventions are being tested in trial NCT06313593?
The interventions under investigation include: Standard disease-directed therapy (DRUG), INCB160058 (DRUG).
Who is sponsoring clinical trial NCT06313593?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06313593 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloproliferative Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06313593's enrollment target sits among peer trials
186 4th of 8 higher than 5 of 8 other Myeloproliferative Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloproliferative Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
RECRUITING · Phase 1
-
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
ACTIVE NOT RECRUITING · Phase 1
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI